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Abstract
Background: Delayed-type hypersensitivity (DTH) testing, an in vivo assessment of cell-mediated immunity, is a
predictor of HIV disease progression beyond CD4 cell count. We investigated whether preserved DTH
responsiveness was characteristic of HIV controllers compared to non-controllers and individuals on suppressive
HAART.
Findings: DTH testing consisted of ≥ 3 recall antigens applied approximately every 6 months. DTH responses were
classified by the number of positive skin tests: anergic (0), partial anergic (1), or non-anergic (≥ 2). HIV controllers
were compared to treatment naïve non-controllers (n = 3822) and a subgroup of non-controllers with VL < 400
copies/mL on their initial HAART regimen (n = 491). The proportion of non-anergic results at first DTH testing was
similar for HIV controllers compared to non-controllers (81.9% vs. 77.6%; P = 0.22), but tended to be greater in HIV
controllers compared to the HAART subgroup (81.9% vs. 74.5%; P = 0.07). Complete anergy was observed in 14
(10.1%) HIV controllers with CD4 counts ≥ 400 cells/uL. For longitudinal testing, the average percentage of non-
anergic DTH determinations per participant was higher in HIV controllers compared to non-controllers (81.2 ±
31.9% vs. 70.7 ± 36.8%; P = 0.0002), however this difference was eliminated with stratification by CD4 count: 200-
399 (83.4 ± 35.6% vs. 71.9 ± 40.9%; P = 0.15) and > 400 cells/uL (81.2 ± 31.5% vs. 80.4 ± 32.7%; P = 0.76).
Conclusions: Spontaneous virologic control was not associated with DTH responsiveness, and several HIV
controllers were anergic despite having elevated CD4 counts. These findings suggest that cellular immunity
assessed by DTH is not a principal factor contributing to spontaneous virologic suppression in HIV controllers.
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Introduction
Delayed-type hypersensitivity (DTH) testing can be used
as an in vivo assessment of cell-mediated immunity
(CMI). Compared to HIV-seronegative individuals,
patients with HIV typically have less favorable DTH
responses, particularly in the setting of low CD4 cell
counts where anergy is common [1,2]. Among HIV-
infected persons on highly active antiretroviral therapy
(HAART), DTH responsiveness has been shown to be
both a predictor of treatment outcomes and a marker
for improved CMI [3-5].
Elite and viremic controllers, collectively termed HIV
controllers, are characterized by the ability to sponta-
neously control plasma HIV viral load (VL) for pro-
longed periods without HAART [6,7]. HIV controllers
typically have several characteristics similar to HAART-
suppressed individuals, including elevated CD4 counts
and reduced risk of AIDS and death [6]. We investigated
whether DTH responsiveness was greater in HIV con-
trollers compared to non-controllers and HAART sup-
pressors in the U.S. Military HIV Natural History Study
(NHS).
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The NHS is a prospective observational cohort of over
5300 military members, dependents, and beneficiaries
with HIV-1 infection followed in the military healthcare
system since 1986 [8]. Participants providing informed
consent in this IRB-approved study are evaluated
approximately every 6 months at selected US military
treatment facilities.
HIV controllers are composed of 2 mutually exclusive
groups termed elite and viremic controllers as defined pre-
viously [6]. Elite controllers were defined as having ≥ 3
plasma VLs below the limit of detection spanning ≥ 12
months without HAART. Viremic controllers were
defined as having ≥ 3V L s≤ 2000 copies/mL over a period
of ≥ 12 months without HAART. Non-controllers were
cohort participants not meeting HIV controller definitions.
A subset of non-controllers, termed HAART suppressors,
was defined as those achieving a VL < 400 copies/mL
within the first 6 months of their initial HAART regimen.
DTH testing was performed according to standardized
protocols as previously described [1,2,5,9]. A total of
0.1 mL of each antigen was applied to the forearm intra-
dermally according to the Mantoux method and a positive
test was defined as ≥ 5 mm of induration after 48 h. The
most recent antigens and concentrations included tetanus
toxoid (Lederle 1.6 Lf/mL; 1:100 dilution), mumps (Con-
naught, 40 CFU/mL), trichophyton (Holister-Stier, 1:500
dilution), and candida (Walter Reed Army Institute of
Research, 200 PNU/mL). Participants received a panel of
3-4 antigens, with the majority receiving 3 antigens as tri-
chophyton was removed from the market in 1996. DTH
responses were categorized by the number of positive skin
tests: anergic (0), partial anergic (1), or non-anergic (≥ 2)
as previously described [1].
First DTH response refers to the initial DTH determi-
nation performed during the period of spontaneous vir-
ologic control for HIV controllers and the first available
DTH test for non-controllers. First DTH response for
HAART suppressors was defined as the DTH determi-
nation after 2 years of HAART. The proportion of all
DTH determinations with non-anergic results was also
studied for those with ≥ 2 DTH testing episodes.
Statistical comparisons were made between HIV con-
trollers and both non-controllers and HAART suppres-
sors. Demographic and HIV-1 characteristics were
compared using t-tests for continuous variables and chi-
square tests for categorical variables. First DTH test
results were compared using chi-square tests. Longitudi-
nal DTH measures for each subject were summarized as
the percentage of test results that were non-anergic and
between-group comparisons were made using weighted
analysis of variance. Weights were a function of the num-
ber of measurements available per subject and the within
and between subject components of variance of DTH
results. Analyses are presented overall and by CD4 count
at the time of DTH testing. Analysis was also done
adjusting for CD4 count as a continuous variable.
Results
DTH testing was performed in 33 elite and 116 viremic
controllers (Table 1). There were 3822 non-controllers for
comparison, of which 491 also met criteria for the
HAART suppressor subgroup. Both HIV controllers and
non-controllers were predominantly male and approxi-
mately 29 years at HIV-1 diagnosis, but HIV controllers
had a higher proportion of African Americans (P < 0.01).
HIV controllers had both a later calendar year of diagnosis
(1995 ± 6 years) and first DTH test (1997 ± 5) compared
to non-controllers (1991 ± 5 and 1992 ± 5, respectively;
P < 0.01 for both). HIV controllers had a lower log10 VL at
diagnosis (3.0 ± 0.8) compared to non-controllers (4.3 ±
0.8; P < 0.01) and the HAART suppressor subgroup (4.4 ±
0.8; P < 0.01). Mean CD4 counts were also higher at HIV-
1 diagnosis for HIV controllers (723 ± 234 cells/uL) com-
pared to non-controllers (539 ± 275 cells/uL; P < 0.01)
and the HAART suppressor subgroup (505 ± 243 cells/uL;
P < 0.01). The number of DTH testing episodes for HIV
controllers and non-controllers was similar (5.5 ± 4.8 vs.
5.5 ± 4.7; P = 0.84).
A non-anergic DTH determination (response to ≥ 2
antigens) was not universally observed for elite (72.7%)
and viremic controllers (84.5%) at first DTH evaluation.
In the combined group of HIV controllers, the percen-
tage of non-anergic DTH results was somewhat higher
than non-controllers (81.9% versus 77.6%) but the differ-
ence was not significant (P = 0.22) (Table 2). When stra-
tified by CD4 count at DTH testing, the proportion with
non-anergic DTH tests was no different for HIV control-
lers compared to non-controllers, with 70% vs. 74.2%
non-anergic at CD4 200-399 cells/uL (P = 0.76) and
82.6% vs. 84.7% at CD4 ≥ 400 cells/uL (P = 0.52), respec-
tively. In a model adjusted for CD4 count there was no
significant differences between groups. Surprisingly, 4
(12.9%) elite and 10 (9.3%) viremic controllers were com-
pletely anergic despite having CD4 counts ≥ 400 cells/uL.
The average percent of all DTH determinations with a
non-anergic result was high for both elite (78.0 ± 31.3%)
and viremic (82.0 ± 32.2%) controllers. Compared to
non-controllers, the average percent with a non-anergic
result was higher in HIV controllers (81.2 ± 31.9% vs.
70.7 ± 36.8%; P < 0.01). However, after adjusting for
CD4 count there was no significant difference between
groups (P = 0.98); among those with CD4 ≥ 400 cells/
uL, the average percent non-anergic was nearly identical
(81.2 vs. 80.4%, P = 0.76).
Of the 491 HAART suppressors, the majority (70.1%)
were prescribed protease inhibitor-based regimens and
the mean CD4 count and log10 VL at HAART initiation
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tively. At the time of first DTH determination 2 years
after starting HAART, the median increase in CD4
count was 226 cells/uL (IQR, 108-356). HIV controllers
tended to have a greater proportion of non-anergic
results compared to those on ≥ 24 months of HAART
(81.9% vs. 74.5%; P = 0.07; Table 2), however this differ-
ence diminished when stratified by CD4 level (82.6% vs.
76.5%; P = 0.14 for CD4 ≥ 400 cells/uL).
Discussion
HIV controllers, though defined by virologic criteria, are
typically associated with elevated CD4 cell counts and
improved clinical outcomes [6,7]. We determined that
spontaneous virologic suppression in HIV controllers
was independent of DTH responsiveness since nearly
one-fifth of HIV controllers displayed partial or complete
anergy at first DTH testing despite higher CD4 counts,
and a similar proportion of non-anergic results were
observed between HIV controllers and non-controllers
when stratified by CD4 count.
A previous study [4] in the Air Force component of
our HIV-infected population showed that 86% of partici-
pants with CD4 count > 400 cells/uL were non-anergic,
similar to the 83% and 85% observed for HIV controllers
and non-controllers, respectively in our study. Though
HIV controllers typically have preserved DTH responses
at higher CD4 cell counts, a proportion displayed anergy
to recall antigens. Among elite controllers, 26% demon-
strated anergy (4 partial and 4 complete) at first DTH
testing despite having CD4 cell counts ≥ 400 cells/uL.
This suggests that factors contributing to virologic con-
trol and DTH responsiveness do not completely overlap.
We previously showed that a favorable CCL3L1-CCR5
genetic risk group (GRG) status, which is enriched in
the HIV controller population, was associated with
greater DTH responsiveness [5]. However, approxi-
mately 25% of HIV controllers did not have a favorable
CCL3L1-CCR5 GRG status which suggests that elite
and viremic controllers may represent a convergence of
heterogeneous phenotypes with the common feature of
spontaneous virologic control, and reinforces the con-
cept of the presence of both viral load dependent and
independent mechanisms of HIV-1 pathogenesis and
host response.
In addition to reconstitution of CD4 cells, HAART
impacts the immune system in other ways including the
improvement of serologic response to vaccinations [10],
reducing immune activation [11], and enhancing DTH
responses [3,12]. In one study, suppression of plasma vire-
mia was necessary for improved DTH responsiveness on
HAART [13]. For HAART-naïve individuals, lower steady-
state VL has also been associated with greater DTH respon-
siveness [5]. In comparison to participants with ≥ 2 years of
suppressive HAART in our study, HIV controllers had a
greater tendency for non-anergic DTH responses (81.9% vs.
74.5%; P = 0.07) and a similar pattern was observed when
stratified by CD4 count. HAART suppressors also displayed
less DTH responsiveness than the non-controllers group as
a whole. This may be due to enrichment with participants
Table 1 Characteristics of HIV controllers, non-controllers, and HAART suppressors
Characteristic Elite
Controllers
Viremic
Controllers
HIV
Controllers
Non-
Controllers
P-value
HIV Controllers vs.
Non- controllers
HAART
Suppressors
P-value HIV Controllers
vs. HAART Suppressors
Number of Participants, n 33 116 149 3822 - 491 -
Age at HIV Diagnosis (years) 29.3 ± 7.4 28.8 ± 6.6 28.9 ± 6.8 29.4 ± 7.8 0.45 31.1 ± 7.9 0.002
Gender, Male 30 (90.9) 102 (87.9) 132 (88.6) 3512 (91.9) 0.15 450 (91.6) 0.25
Race/Ethnicity
European American 12 (36.4) 41 (35.3) 53 (35.6) 1725 (45.2) 0.021 244 (49.7) 0.002
African American 21 (63.6) 64 (55.2) 85 (57.0) 1668 (43.7) 0.001 192 (39.1) < 0.001
Hispanic 0 (0.0) 6 (5.2) 6 (4.0) 300 (7.9) 0.09 38 (7.7) 0.12
Other 0 (0.0) 5 (4.3) 5 (3.4) 127 (3.4) 0.98 17 (3.5) 0.95
Year of HIV Diagnosis 1993 ± 6 1995 ± 6 1995 ± 6 1991 ± 5 < 0.001 1995 ± 5 0.90
Mean CD4
+ Count at HIV
Diagnosis (cells/uL)
689.7 ±
241.6
731.9 ±
232.6
723.4 ±
234.0
539.2 ±
275.1
< 0.001 504.7 ±
242.6
< 0.001
Mean Viral Load at HIV
Diagnosis (log10 copies/mL)
2.7 ± 0.8 3.0 ± 0.8 3.0 ± 0.8 4.3 ± 0.8 < 0.001 4.4 ± 0.8 < 0.001
Year of First DTH Test
a 1997 ± 4 1997 ± 5 1997 ± 5 1992 ± 5 < 0.001 2000 ± 2 < 0.001
Mean Number of DTH
Testing Episodes
4.9 ± 4.2 5.7 ± 5.0 5.5 ± 4.8 5.5 ± 4.7 0.84 N/A N/A
NOTE. HIV controllers, combined group of elite and viremic controllers; HAART suppressors, subgroup of non-controllers on suppressive HAART; all values are
number, percent or SD unless otherwise specified
a First DTH for HAART subgroup defined as first DTH test 2 years after start of initial HAART regimen
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tion of HAART.
Previous studies validated the use of multiple DTH
antigen panels for studying various HIV outcomes
[1,2,9]. Although a similar approach was used, a limita-
tion of our study was that a comparison of individual
antigens was not able to be performed. In addition,
other virus-related factors that can influence HIV-1 dis-
ease progression, such as viral fitness and HIV clade,
were not examined. Future studies investigating non-
anergic versus anergic DTH responses, including higher
resolution ex vivo assays of CMI to recall antigens and
other immunologic studies, may provide additional
insight into DTH responsiveness.
Although virologic control occurred by different
mechanisms, both HIV controllers and HAART sup-
pressors commonly displayed preserved DTH responses,
especially at higher CD4 counts. A proportion of HIV
controllers were anergic at DTH testing despite higher
CD4 cell counts. Thus, HIV controller phenotypes
appear to achieve virologic control by disparate mechan-
isms than those involving DTH responsiveness to recall
antigens.
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Non-anergic 24 (72.7) 98 (84.5) 122 (81.9) 2965 0.22 366 (74.5) 0.07
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